GlassScriptPhysician profile
Charles S Dunlap
NPI 1376503870
$1,242.26
in general payments reported to CMS, 2019-2025
13 companies · $388 in 2025
The $388 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $17.31 · 2021: $33.66 · 2022: $98.48 · 2023: $147 · 2024: $368 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $902.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $602.03 | 2022-2025 | Azstarys |
| Pfizer INC. | $170.30 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $138.89 | 2023-2025 | |
| Cranial Technologies, INC | $105.39 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $50.36 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Seqirus USA INC | $37.04 | 2023 | Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $33.22 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $29.04 | 2019 | |
| Shire North American Group INC | $18.26 | 2019 | |
| Genentech USA, INC. | $17.31 | 2020 | |
| Supernus Pharmaceuticals, INC. | $15.02 | 2024 | Qelbree |
| Organon LLC | $14.37 | 2025 | |
| Arbor Pharmaceuticals, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.